Quantitative hepatitis B core antibody level is associated with inflammatory activity in treatment-naïve chronic hepatitis B patients
نویسندگان
چکیده
Previous studies have shown that hepatitis B core antibody (anti-HBc) levels vary during different phases of disease in treatment-naïve chronic hepatitis B (CHB) patients and can be used as a predictor of both interferon-α and nucleoside analogue therapy response. However, there is no information on the association between the quantitative serum anti-HBc (qAnti-HBc) level and liver inflammation in CHB patients. Therefore, we investigated these relationships in a large cohort of treatment-naïve CHB patients. A total of 624 treatment-naïve CHB patients were included in the study. The serum qAnti-HBc level was moderately correlated with ALT and AST levels (P < 0.001) in both hepatitis B e antigen-positive (HBeAg [+]) and HBeAg-negative (HBeAg [-]) CHB patients. CHB patients with no to mild inflammation (G0-1) had significantly lower serum qAnti-HBc levels than patients with moderate to severe inflammation (G2-4) (P < 0.001). Receiver operating characteristic analysis suggested that a serum qAnti-HBc cut-off value of 4.36 log10 IU/mL provided a sensitivity of 71.68%, specificity of 73.81%, positive predictive value of 78.43%, and negative predictive value of 66.24% in HBeAg (+) CHB patients with moderate to severe inflammation (G≥2). A cut-off value of 4.62 log10 IU/mL provided a sensitivity of 54.29%, specificity of 90.00%, positive predictive value of 95.00%, and negative predictive value of 36.00% in HBeAg (-) CHB patients with moderate to severe inflammation (G≥2). Serum qAnti-HBc levels were positively associated with liver inflammation grade. Furthermore, we identified optimal serum qAnti-HBc cut-off values for the prediction of inflammation activity in both HBeAg (+) and HBeAg (-) treatment-naïve CHB patients.
منابع مشابه
Significance of Hepatitis B Core Antibody as the Only Marker of Hepatitis B Virus Infection in High Risk Patients
Background and Objective: Presence of hepatitis B core antibody (anti-HBc) in the absence of hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs) is defined, as isolated anti-HBc. little is known about the clinical significance of the isolated anti-HBc in hepatitis B virus (HBV) infections. The aim of this study was to assess the significance of anti-HBc as the onl...
متن کاملExpression of Human Cytokine Genes Associated with Chronic Hepatitis B Disease Progression
Background: Hepatitis viruses are non-cytopathic viruses that lead to the infection and pathogenesis of liver diseases as a result of immunologically mediated event. Objective: To investigate the expression of human inflammatory cytokines in chronic hepatitis B patients according to the severity of the infection. Methods: We recruited a total of 120 patients, 40 of whom from cirrhotic, 40 non-c...
متن کاملIncidence of Hepatitis B virus Surface Antigen (HBsAg) Mutations in Naïve Treated of Chronic Carriers from Tehran Metropolis, Iran
Abstract Background: Naturally occurred hepatitis B virus (HBV) with surface mutations in a variety of chronic hepatitis B (CHB) patients who have received no vaccine or HBIG bearing substitutions in surface protein, have been reported. Objectives: Current knowledge concerning the prevalence of these naturally occurring surface antigen mutations among Iranian carriers is limited. Patients and M...
متن کاملEvaluation of miR-101 Level in Patients with Chronic Hepatitis B Virus Infection and Liver Cirrhosis
ABSTRACT Background and Objective: MiRNAs are small RNAs that are expressed in most eukaryotes, and can regulate gene expression by attaching to the 3’ end of target mRNA. MicroRNA-101 (miR-101) post-transcriptional regulation is important for host-virus interactions. In addition, miR-101 has a tumor suppressive role in liver cancer and metastasis, an...
متن کاملبررسی اثر واکسیناسیون هپاتیت B و نقش ایمنیزایی دوز یادآور در بیماران با تزریق خون مداوم
Background & Aim: Hepatitis B vaccine is in national vaccination programs. In healthy individuals the immune response is complete d by three-dose injections in 95% of cases and remains complete with time. However, in patients with chronic transfusion this immune response may be incomplete . In such patients, it is advised to check HBs antibody periodically, and use booster dose in cases with ...
متن کامل